Figures & data
Table 1. Patient characteristics (n = 144).
Table 2. Perioperative adverse events of HIFU ablation.
Table 3. Overall survival of PVTT and its subgroups.
Table 4. OS and AEs of various treatment options for HCC complicated with PVTT.
Cao Y, Sun T, Guo X, et al. Sorafenib versus apatinib both combined transarterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombosis: a comparative retrospective study. Front Oncol. 2021;11:673378. Tang Q, Huang W, Liang J, et al. Efficacy and safety of transarterial chemoembolization in elderly patients of advanced hepatocellular carcinoma with portal vein tumor thrombus: a retrospective study. Front Oncol. 2021;11:646410. Zhang XX, Wang C, Zhao W, et al. Efficacy and safety of DEB-TACE combined with apatinib in the treatment of hepatocellular carcinoma with portal vein tumor thrombus. J Interv Radiol. 2021;30(3):282–287. Munire A, Tan Y, Wang HF, et al. Analysis of therapeutic effect and prognostic factors of IMRT combined with sorafenib in the treatment of hepatocellular carcinoma with portal vein thrombosis. Tianjin Med J. 2021;49(5):514–519. Ohkoshi-Yamada M, Kamimura K, Shibata O, et al. Efficacy and safety of the radiotherapy for liver cancer: assessment of local controllability and its role in multidisciplinary therapy. Cancers. 2020;12(10):2955. Li Y, Li H, Hu H, et al. Efficacy and safety of transcatheter arterial chemoembolization combined with either (125)I seed implantation or apatinib in hepatocellular carcinoma with portal vein tumor thrombosis: a retrospective comparative study. J Cancer Res Ther. 2020;16(7):1691–1697. Li Z, Si G, Jiao DC, et al. Portal vein stenting combined with (125)I particle chain implantation followed by as(2)O(3) in the treatment of hepatocellular carcinoma with portal vein tumour thrombus. Biomed Res Int. 2020;2020:1–7. Liang J, Ge NJ, Guo XL, et al. Clinical analysis of percutaneous radiofrequency ablation combined with TACE in treatment of hepatocellular carcinoma with type III portal vein tumor thrombus. J Hepatobil Surg. 2020;28(5):345–348. Yuan G, Cheng X, Li Q, et al. Safety and efficacy of camrelizumab combined with apatinib for advanced hepatocellular carcinoma with portal vein tumor thrombus: a multicenter retrospective study. Onco Targets Ther. 2020;13:12683–12693. Ni JY, Sun HL, Luo JH, et al. Transarterial chemoembolization and sorafenib combined with microwave ablation for advanced primary hepatocellular carcinoma: a preliminary investigation of safety and efficacy. Cancer Manag Res. 2019;11:9939–9950. Choi JH, Chung WJ, Bae SH, et al. Randomized, prospective, comparative study on the effects and safety of sorafenib vs. hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma with portal vein tumor thrombosis. Cancer Chemother Pharmacol. 2018;82(3):469–478. Su F, Chen KH, Liang ZG, et al. Comparison of three-dimensional conformal radiotherapy and hepatic resection in hepatocellular carcinoma with portal vein tumor thrombus. Cancer Med. 2018;7(9):4387–4395. Jia Z, Jiang G, Tian F, et al. A systematic review on the safety and effectiveness of yttrium-90 radioembolization for hepatocellular carcinoma with portal vein tumor thrombosis. Saudi J Gastroenterol. 2016;22(5):353–359. Lee SU, Park JW, Kim TH, et al. Effectiveness and safety of proton beam therapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis. Strahlenther Onkol. 2014;190(9):806–814. Data availability statement
All data are available upon request.